APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mental Disorders Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mental Disorders Drugs Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchMental Disorders Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Mental Disorders Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Mental Disorders Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mental Disorders Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Mental Disorders Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Mental Disorders Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mental Disorders Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mental Disorders Drugs market include Johnson & Johnson, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mental Disorders Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mental Disorders Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mental Disorders Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mental Disorders Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Mental Disorders Drugs Segment by Company

Johnson & Johnson

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Bristol-Myers Squibb

Abbott Laboratories

Mental Disorders Drugs Segment by Type

Drugs for Childhood and Adolescent Mental Illness

Drugs for Schizophrenia

Anxiolytics

Antipsychotics

Antidepressants

Sleep Disorders

Drugs to Treat Cognitive Disorders

Drugs for the Treatment of Substance and Alcohol Addiction

Others

Mental Disorders Drugs Segment by Application

Adolescents

Children

Adults

Mental Disorders Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mental Disorders Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mental Disorders Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mental Disorders Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Mental Disorders Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mental Disorders Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mental Disorders Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mental Disorders Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mental Disorders Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mental Disorders Drugs industry.

Chapter 3: Detailed analysis of Mental Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mental Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mental Disorders Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mental Disorders Drugs Industry Trends Table 2. Mental Disorders Drugs Industry Drivers Table 3. Mental Disorders Drugs Industry Opportunities and Challenges Table 4. Mental Disorders Drugs Industry Restraints Table 5. Global Mental Disorders Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mental Disorders Drugs Revenue Share by Company (2021-2026) Table 7. Global Mental Disorders Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Mental Disorders Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Mental Disorders Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Mental Disorders Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mental Disorders Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Mental Disorders Drugs Company, Product Type & Application Table 13. Global Mental Disorders Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mental Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Drugs for Childhood and Adolescent Mental Illness Table 18. Significant Companies of Drugs for Schizophrenia Table 19. Significant Companies of Anxiolytics Table 20. Significant Companies of Antipsychotics Table 21. Significant Companies of Antidepressants Table 22. Significant Companies of Sleep Disorders Table 23. Significant Companies of Drugs to Treat Cognitive Disorders Table 24. Significant Companies of Drugs for the Treatment of Substance and Alcohol Addiction Table 25. Significant Companies of Others Table 26. Global Mental Disorders Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Mental Disorders Drugs Sales Volume by Type (2021-2026) & (W Units) Table 28. Global Mental Disorders Drugs Sales Volume by Type (2027-2032) & (W Units) Table 29. Global Mental Disorders Drugs Sales Volume Share by Type (2021-2026) Table 30. Global Mental Disorders Drugs Sales Volume Share by Type (2027-2032) Table 31. Global Mental Disorders Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Mental Disorders Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 33. Global Mental Disorders Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 34. Global Mental Disorders Drugs Sales Value Share by Type (2021-2026) Table 35. Global Mental Disorders Drugs Sales Value Share by Type (2027-2032) Table 36. Significant Companies of Adolescents Table 37. Significant Companies of Children Table 38. Significant Companies of Adults Table 39. Global Mental Disorders Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Mental Disorders Drugs Sales Volume by Application (2021-2026) & (W Units) Table 41. Global Mental Disorders Drugs Sales Volume by Application (2027-2032) & (W Units) Table 42. Global Mental Disorders Drugs Sales Volume Share by Application (2021-2026) Table 43. Global Mental Disorders Drugs Sales Volume Share by Application (2027-2032) Table 44. Global Mental Disorders Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Mental Disorders Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Mental Disorders Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Mental Disorders Drugs Sales Value Share by Application (2021-2026) Table 48. Global Mental Disorders Drugs Sales Value Share by Application (2027-2032) Table 49. Global Mental Disorders Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 50. Global Mental Disorders Drugs Sales by Region (2021-2026) & (W Units) Table 51. Global Mental Disorders Drugs Sales Market Share by Region (2021-2026) Table 52. Global Mental Disorders Drugs Sales by Region (2027-2032) & (W Units) Table 53. Global Mental Disorders Drugs Sales Market Share by Region (2027-2032) Table 54. Global Mental Disorders Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Mental Disorders Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Mental Disorders Drugs Sales Value Share by Region (2021-2026) Table 57. Global Mental Disorders Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Mental Disorders Drugs Sales Value Share by Region (2027-2032) Table 59. Global Mental Disorders Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 60. Global Mental Disorders Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 61. Global Mental Disorders Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. Global Mental Disorders Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Mental Disorders Drugs Sales by Country (2021-2026) & (W Units) Table 64. Global Mental Disorders Drugs Sales Market Share by Country (2021-2026) Table 65. Global Mental Disorders Drugs Sales by Country (2027-2032) & (W Units) Table 66. Global Mental Disorders Drugs Sales Market Share by Country (2027-2032) Table 67. Global Mental Disorders Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Mental Disorders Drugs Sales Value Market Share by Country (2021-2026) Table 69. Global Mental Disorders Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Mental Disorders Drugs Sales Value Market Share by Country (2027-2032) Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Mental Disorders Drugs Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly Mental Disorders Drugs Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Pfizer Mental Disorders Drugs Product Portfolio Table 85. Pfizer Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Mental Disorders Drugs Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Mental Disorders Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Bristol-Myers Squibb Company Information Table 97. Bristol-Myers Squibb Business Overview Table 98. Bristol-Myers Squibb Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bristol-Myers Squibb Mental Disorders Drugs Product Portfolio Table 100. Bristol-Myers Squibb Recent Development Table 101. Abbott Laboratories Company Information Table 102. Abbott Laboratories Business Overview Table 103. Abbott Laboratories Mental Disorders Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Abbott Laboratories Mental Disorders Drugs Product Portfolio Table 105. Abbott Laboratories Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Mental Disorders Drugs Distributors List Table 109. Mental Disorders Drugs Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Mental Disorders Drugs Product Image Figure 2. Global Mental Disorders Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mental Disorders Drugs Sales (2021-2032) & (W Units) Figure 5. Global Mental Disorders Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Mental Disorders Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Drugs for Childhood and Adolescent Mental Illness Image Figure 10. Drugs for Schizophrenia Image Figure 11. Anxiolytics Image Figure 12. Antipsychotics Image Figure 13. Antidepressants Image Figure 14. Sleep Disorders Image Figure 15. Drugs to Treat Cognitive Disorders Image Figure 16. Drugs for the Treatment of Substance and Alcohol Addiction Image Figure 17. Others Image Figure 18. Global Mental Disorders Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Mental Disorders Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 20. Global Mental Disorders Drugs Sales Volume Share by Type (2021-2032) Figure 21. Global Mental Disorders Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Mental Disorders Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Mental Disorders Drugs Sales Value Share by Type (2021-2032) Figure 24. Adolescents Image Figure 25. Children Image Figure 26. Adults Image Figure 27. Global Mental Disorders Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Mental Disorders Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Mental Disorders Drugs Sales Volume Share by Application (2021-2032) Figure 30. Global Mental Disorders Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Mental Disorders Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Mental Disorders Drugs Sales Value Share by Application (2021-2032) Figure 33. Global Mental Disorders Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 34. Global Mental Disorders Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Mental Disorders Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Mental Disorders Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. North America Mental Disorders Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Mental Disorders Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Mental Disorders Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. South America Mental Disorders Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Mental Disorders Drugs Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Mental Disorders Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Mental Disorders Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Mental Disorders Drugs Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Mental Disorders Drugs Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs for Childhood and Adolescent Mental Illness
  • Drugs for Schizophrenia
  • Anxiolytics
  • Antipsychotics
  • Antidepressants
  • Sleep Disorders
  • Drugs to Treat Cognitive Disorders
  • Drugs for the Treatment of Substance and Alcohol Addiction
  • Others
Applications
  • Adolescents
  • Children
  • Adults
Companies covered
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Bristol-Myers Squibb
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mental Disorders Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Mental Disorders Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Mental Disorders Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mental Disorders Drugs Market Dynamics
  1. 2.1 Mental Disorders Drugs Industry Trends
  2. 2.2 Mental Disorders Drugs Industry Drivers
  3. 2.3 Mental Disorders Drugs Industry Opportunities and Challenges
  4. 2.4 Mental Disorders Drugs Industry Restraints
3 Mental Disorders Drugs Market by Company
  1. 3.1 Global Mental Disorders Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Mental Disorders Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Mental Disorders Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Mental Disorders Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Mental Disorders Drugs Company Ranking (2024-2026)
  6. 3.6 Global Mental Disorders Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Mental Disorders Drugs Company Product Type and Application
  8. 3.8 Global Mental Disorders Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mental Disorders Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mental Disorders Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mental Disorders Drugs Market by Type
  1. 4.1 Mental Disorders Drugs Type Introduction
  2. 4.1.1 Drugs for Childhood and Adolescent Mental Illness
  3. 4.1.2 Drugs for Schizophrenia
  4. 4.1.3 Anxiolytics
  5. 4.1.4 Antipsychotics
  6. 4.1.5 Antidepressants
  7. 4.1.6 Sleep Disorders
  8. 4.1.7 Drugs to Treat Cognitive Disorders
  9. 4.1.8 Drugs for the Treatment of Substance and Alcohol Addiction
  10. 4.1.9 Others
  11. 4.2 Global Mental Disorders Drugs Sales Volume by Type
  12. 4.2.1 Global Mental Disorders Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Mental Disorders Drugs Sales Volume by Type (2021-2032)
  14. 4.2.3 Global Mental Disorders Drugs Sales Volume Share by Type (2021-2032)
  15. 4.3 Global Mental Disorders Drugs Sales Value by Type
  16. 4.3.1 Global Mental Disorders Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Mental Disorders Drugs Sales Value by Type (2021-2032)
  18. 4.3.3 Global Mental Disorders Drugs Sales Value Share by Type (2021-2032)
5 Mental Disorders Drugs Market by Application
  1. 5.1 Mental Disorders Drugs Application Introduction
  2. 5.1.1 Adolescents
  3. 5.1.2 Children
  4. 5.1.3 Adults
  5. 5.2 Global Mental Disorders Drugs Sales Volume by Application
  6. 5.2.1 Global Mental Disorders Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mental Disorders Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Mental Disorders Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Mental Disorders Drugs Sales Value by Application
  10. 5.3.1 Global Mental Disorders Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Mental Disorders Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Mental Disorders Drugs Sales Value Share by Application (2021-2032)
6 Mental Disorders Drugs Regional Sales and Value Analysis
  1. 6.1 Global Mental Disorders Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mental Disorders Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Mental Disorders Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Mental Disorders Drugs Sales by Region (2027-2032)
  5. 6.3 Global Mental Disorders Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mental Disorders Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mental Disorders Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mental Disorders Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Mental Disorders Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mental Disorders Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Mental Disorders Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mental Disorders Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Mental Disorders Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mental Disorders Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mental Disorders Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mental Disorders Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Mental Disorders Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mental Disorders Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mental Disorders Drugs Sales Value Share by Country, 2025 VS 2032
7 Mental Disorders Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Mental Disorders Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mental Disorders Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mental Disorders Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Mental Disorders Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Mental Disorders Drugs Sales by Country (2027-2032)
  6. 7.4 Global Mental Disorders Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mental Disorders Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mental Disorders Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mental Disorders Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mental Disorders Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mental Disorders Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Mental Disorders Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Mental Disorders Drugs Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Mental Disorders Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Mental Disorders Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Mental Disorders Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Mental Disorders Drugs Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
  37. 8.7 Abbott Laboratories
  38. 8.7.1 Abbott Laboratories Company Information
  39. 8.7.2 Abbott Laboratories Business Overview
  40. 8.7.3 Abbott Laboratories Mental Disorders Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Abbott Laboratories Mental Disorders Drugs Product Portfolio
  42. 8.7.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mental Disorders Drugs Value Chain Analysis
  2. 9.1.1 Mental Disorders Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mental Disorders Drugs Sales Mode & Process
  6. 9.2 Mental Disorders Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mental Disorders Drugs Distributors
  9. 9.2.3 Mental Disorders Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst